Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers

Developing an immunogen that elicits broadly neutralizing antibodies (bNAbs) is an elusive but important goal of HIV vaccine research, especially after the recent failure of the leading T cell based HIV vaccine in human efficacy trials. Even if such an immunogen can be developed, most animal model s...

Descripción completa

Detalles Bibliográficos
Autores principales: Hessell, Ann J., Rakasz, Eva G., Poignard, Pascal, Hangartner, Lars, Landucci, Gary, Forthal, Donald N., Koff, Wayne C., Watkins, David I., Burton, Dennis R.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2674935/
https://www.ncbi.nlm.nih.gov/pubmed/19436712
http://dx.doi.org/10.1371/journal.ppat.1000433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2674935/
https://www.ncbi.nlm.nih.gov/pubmed/19436712
http://dx.doi.org/10.1371/journal.ppat.1000433

Ejemplares similares